Method of generating natural killer cells and dendritic cells from human embryonic stem cell-derived hemangioblasts
View Patent ↗This invention provides methods of generating natural killer (NK) cells and dendritic cells (DCs). The methods utilize human hemangioblasts as intermediate cells to generate the NK cells and DCs. In various embodiments, the methods do not require the use of stromal feeder layers.
1. A method to generate dendritic cells (DCs), comprising:
providing hemangioblasts;
culturing the hemangioblasts in liquid media comprising human serum, SCF, FL, IL3 and GM-CSF;
adding IL4 to the liquid media; and
further culturing the hemangioblasts to generate the DCs.
2. The method of claim 1 , wherein culturing the hemangioblasts is for about 7 to 11 days.
3. The method of claim 1 , wherein further culturing of the hemangioblast after the addition of IL4 is for about 8 to 10 days.
4. The method of claim 1 , further comprising adding a cytokine mixture comprising IL1b, TNFα and IL6 to induce maturation of the DCs.
5. The method of claim 4 , wherein the cytokine mixture is added for about 48 hours.
6. The method of claim 4 , wherein the cytokine mixture further comprises a cytokine selected from the group consisting of PGE2, IFNα2b, poly I:C, IFNγ and combinations thereof.
7. The method of claim 1 , further comprising adding LPS, IFNγ and/or S-28463 to stimulate IL12p70 production from the DCs and/or HLA-DR expression from the DCs.
8. The method of claim 1 , wherein the concentration of SCF is about 20-100 ng/ml, FL is about 10-50 ng/ml, IL3 is about 5-50 ng/ml, GM-CSF is about 50-100 ng/ml, and IL4 is about 50-100 ng/ml.
9. The method of claim 4 , wherein the concentration of IL1b is about 10 ng/ml, TNFγ is about 10 ng/ml, and IL6 is about 150 ng/ml.
10. The method of claim 6 , wherein the concentration of PGE2 is about 1 μg/ml, IFNα2b is about 3000 units/ml, poly I:C is about 20 μg/ml, and IFNγ is about 20 ng/ml.
11. The method of claim 1 , wherein the DCs are mature DCs and express CD83.
12. The method of claim 1 , wherein the DCs are mature DCs and the expression of CD209, HLA DR and/or CD11c is increased.